Chardan Capital Maintains Buy on Stoke Therapeutics, Raises Price Target to $35

Benzinga · 01/05 13:24
Chardan Capital analyst Keay Nakae maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $24 to $35.